AIM ImmunoTech outlines recent progress across development pipeline

AIM ImmunoTech highlighted recent accomplishments and provided a business outlook. AIM‘s dsRNA product candidate, Ampligen, is being evaluated as a combinational therapy for the treatment of a variety of solid tumor types in multiple clinical trials – both underway and planned – at major cancer research centers around the country. Recent Highlights: AMP-518 Clinical Study: Phase 2 study evaluating Ampligen as a potential therapeutic for people with the Post-COVID condition of fatigue: Completed treatment in study and Reported positive topline results offering preliminary evidence that Ampligen may reduce fatigue in subjects with Post-COVID conditions. Bolstered intellectual property estate with issuance of key U.S. patent for Ampligen in combination with an anti-PD-L1 antibody for the treatment of cancer. DURIPANC Clinical Study: Phase 1b/2 clinical trial combining AIM’s Ampligen with AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor Imfinzi for the treatment of pancreatic cancer; Opened for enrollment and enrolled first subject at Erasmus Medical Center and First subject dosed at Erasmus MC